Oncolytic Virus Cancer Therapy Market will be mostly concentrated in North America | Says FMI Analyst

According to a recent study published by Future Market Insights, the market for Oncolytic Virus Cancer Therapy is forecast to reach a valuation of US$ 22.86 Million by 2023-end, and will eventually reach US$ 250 Million by 2033, growing at an astronomical CAGR of 27%. Governments in various emerging economies have captured steps to raise awareness about various cancer causes.

Government agencies in developed and developing countries are conducting education programs to encourage people to seek early cancer diagnosis, which is expected to increase the number of patients who will be eligible for numerous new therapies.

Due to a significant increase in the number of companies that produce cancer medications, the Asia Pacific region will have the highest ownership stake in the oncolytic virus cancer market. The oncolytic virus therapy market is growing in revenue and earnings as countries such as China and Japan introduce breakthroughs into the market.

For More Insights on this Market, Get A Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16335

Because of the region’s high incidence of cancer, particularly melanoma cancer, North America is expected to be the most valuable region for the global oncolytic virus cancer market. Increased cancer incidences around the world are creating a positive outlook for the market. In line with this, the therapy’s widespread use in the treatment of a wide range of melanomas, including haematological malignancies, lymphoma, leukaemia, and myeloma, is boosting overall growth.

Key Takeaways from the Market Study

• The number of articles on oncolytic virus therapy studies has increased by 395% in the last decade.
• In 2022, Japan’s total oncolytic virus cancer market share was US$ 2 Million, and it is expected to rise during the study period.
• North America is expected to grow at the fastest rate during the forecast period, with a CAGR of 29.5%.
• In the United States in 2021, the market value for oncolytic virus therapies was US$ 8.5 Million
• The global oncolytic virus cancer market is expected to be worth US$ 250 Million.

“As oncology takes a turn for the better, healthcare practitioners are implementing highly advanced ways of diagnosing and treating some of the most debilitating cancers, paving way for enhanced adoption of oncolytic virus cancer therapies,” remarks an FMI analyst.

Have a Conversation with the Analyst @ https://www.futuremarketinsights.com/ask-question/rep-gb-16335

Market Competition

• Amgen, based in the United States, agreed to pay $3.7 billion for the biopharma firm ChemoCentryx in August 2022. As a result of this strategic initiative, Amgen will provide access to Tavneos, the company’s critical therapy that has received therapy confirmation in the EU and Japan. Amgen will be able to expand its reach and develop in regions such as Europe and Asia Pacific as a result of this acquisition.
• In April 2021, Bristol Myers Squibb and PsiOxus Therapeutics enlarged their partnership to investigate PsiOxus Therapeutics’ cancer-killing virus. According to the contract, the collaboration will incorporate Bristol’s checkpoint reagent Opdivo and novel resource NG-641 in various types of tumors. PsiOxus’ oncolytic virus ‘enadenotucirev’ is the basis for NG-641.

Key players in the Oncolytic Virus Cancer market are:

• Oncolytics Biotech Inc.
• Amgen Inc.
• Sorrento Therapeutics
• Transgene SA
• Daiichi Sankyo Company
• Shanghai Sunway Biotech Co Ltd
• Takara Bio Inc.
• PsiOxus Therapeutics
• SillaJen Inc.
• ViroCure

For more Report Customization, connect with us @ https://www.futuremarketinsights.com/customization-available/rep-gb-16335

Key Segments Profiled in the Oncolytic Virus Cancer Therapy Market Industry Survey

By Virus Type:

• Genetically Engineered Oncolytic Viruses
  • Herpes Simplex Virus
  • Adenovirus
  • Vaccinia Virus
• Oncolytic Wild-type Viruses
  • Reovirus
  • Newcastle Disease Virus
  • Vesicular Stomatitis Virus

By Application:

• Solid Tumor
  • Breast Cancer
  • Prostate Cancer
  • Lung Cancer
  • Glioblastoma
• Melanoma
  • Hematological Malignancies
  • Lymphoma
  • Leukemia
  • Myeloma

By End Use:

• Hospitals
• Specialty Clinics
• Cancer Research Institutes

About Future Market Insights (FMI) 

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.

Contact:

Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Browse All Reports: https://www.futuremarketinsights.com/reports
LinkedIn| Twitter| Blogs